Irene Ghobrial, MD

Articles

Disparities in Multiple Myeloma Care: The Path Toward Health Equity

October 28th 2022

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Addressing Healthcare Provider Bias in Multiple Myeloma Management

October 21st 2022

Joint consideration for physician bias in the management of multiple myeloma and how it can be addressed while treating patients belonging to racial and ethnic minority groups.

Improving Access to Clinical Trials in Multiple Myeloma

October 21st 2022

Centering discussion clinical trials in multiple myeloma, panelists review how to improve access to these studies for racial and ethnic minority groups.

Improving Access to Specialty Care in Multiple Myeloma

October 14th 2022

Experts on multiple myeloma share comprehensive insight on how to build better access to specialty care for patients of racial and ethnic minority groups.

Overcoming Barriers to Early Diagnosis in Multiple Myeloma

October 14th 2022

Expert perspectives on how to improve the early detection of multiple myeloma within patients belonging to racial and ethnic minority groups.

Multiple Myeloma: Disparities in Access to Transplantation and Novel Therapy

October 7th 2022

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Multiple Myeloma: Disparities in Access to Specialized Care

October 7th 2022

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

Multiple Myeloma: Disparities in Time to Diagnosis

September 30th 2022

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Societal Determinants of Health in Multiple Myeloma

September 30th 2022

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

March 29th 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma

October 20th 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma. 

Dr. Ghobrial on the Key Objectives of the PROMISE Study in Multiple Myeloma

October 11th 2021

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Dr. Ghorbrial on the Potential Utility of Triplet Therapy in Smoldering Multiple Myeloma

May 15th 2020

Irene Ghobrial, MD, discusses the potential utility of triplet therapy in smoldering multiple myeloma.

Dr. Ghobrial on Triplet Regimen in Smoldering Myeloma

January 31st 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.